Munich receives 2.5 million euros for innovative asthma therapy!

Munich receives 2.5 million euros for innovative asthma therapy!

München, Deutschland - Munich, a hotspot for medical innovations, welcomes a groundbreaking project for asthm treatment! The young company Rnhale, which emerged from the renowned Ludwig Maximilians University in Munich (LMU), received an impressive grant of 2.5 million euros from the European Innovation Council (EIC). This valuable support is intended to develop a new medication based on RNA therapeutic agents to inhale that could help asthma patients, such as ots.at reported. Under the direction of pharmaceutical olivia Merkel, who has years of experience and expertise, research is being carried out on special nanot transport systems that make it possible to bring medication in the body in a targeted manner and to block genes that are involved in the development of diseases.

innovative techniques for asthma therapies

The planned therapies promise to relieve the symptoms of allergic asthma by reducing the expression of cytocin in the airways. The EIC subsidy marks an important step in development: Rnhale wants to support the necessary clinical studies and prepare the technology for the market. Previously, the project was promoted by a proof-of-concept grant of the European Research Council (ERC), which laid the foundation for the establishment of the company, which is now pursuing the vision to treat other respiratory diseases.

In addition, as part of the ERC Consolidator Grant "Ratinhalrna", RNHALE will work on the optimization of inhalable RNA nanocarriers to increase efficiency in viral respiratory diseases. This funding aims to use machine learning and molecular dynamic simulations in order to make the development of polymer-nanocarrier for RNA more specifically, as more information from merkel.cup.uni-muenchen.de . In the future, this will not only be better treated, but also research in the area of ​​respiratory diseases.